After Plummeting 40%, Where Will UnitedHealth Group Stock Be in 1 Year? Here Is What History Suggests.

UnitedHealth Group's stock has declined 40% due to lowered earnings guidance stemming from inaccurate forecasts in its Medicare Advantage business and pharmacy benefit management unit, compounded by the abrupt departure and replacement of its CEO. Despite these challenges, the author draws parallels to CrowdStrike's recovery from a software bug and the long-term upward trend of both UnitedHealth and the S&P 500, suggesting a potential rebound; the author is cautiously optimistic, noting insider buying and anticipating renewed growth next year. The article suggests that the current low stock price reflects already-low expectations, presenting a buying opportunity for patient investors.

Analysis

UnitedHealth Group (UNH) has experienced a significant 40% stock price decline this year, primarily due to internal operational challenges rather than external factors like tariff policies. Management surprised investors by reducing earnings guidance during the first-quarter report, citing inaccurate forecasts for utilization rates in its Medicare Advantage business and reimbursements from its pharmacy benefit management unit. Compounding these issues, CEO Andrew Witty abruptly stepped down and was replaced by former chief executive Stephen Hemsley, introducing leadership uncertainty. Despite these substantial headwinds, the author presents a cautiously optimistic outlook, drawing a parallel to CrowdStrike's stock recovery, which surged 113% from its low approximately one year ago after a reputational issue. The argument posits that both companies offer mission-critical products and that, similar to the broader S&P 500, quality businesses like UnitedHealth tend to recover over the long term. Currently, UNH stock trades near five-year lows, which, coupled with reported insider buying, leads the author to believe that negative sentiment is largely priced in. Management anticipates overcoming current operational hurdles and achieving renewed growth by next year, although 2025 is not expected to be a strong growth year. The author suggests this presents a compelling 'buy the dip' opportunity, projecting shares could be significantly higher in one year. However, it is noted that The Motley Fool Stock Advisor analyst team did not include UnitedHealth in their recent list of top 10 stocks to buy.

Key Decisions for Investors

• Investors should acknowledge the substantial operational difficulties, including misjudged Medicare Advantage utilization and PBM reimbursements, and the recent CEO change that have led to UnitedHealth's significant stock decline and revised earnings guidance.
• Consider the contrarian investment thesis presented, which hinges on the stock's five-year low valuation, insider buying activity, and management's forecast for renewed growth next year, while carefully weighing the risks that current operational challenges may persist.
• Closely monitor upcoming financial reports for tangible evidence of stabilization in the Medicare Advantage and PBM segments, and scrutinize any strategic updates from the reinstated CEO regarding the company's turnaround plan.
• Evaluate the article's bullish stance and the CrowdStrike analogy against the cautionary signal of UnitedHealth's exclusion from The Motley Fool Stock Advisor's top picks, underscoring the need for thorough individual due diligence before making investment decisions.